Harry D. Bear

Department of Surgery, Virginia Commonwealth University- Massey Cancer Center

Affiliated withVirginia Commonwealth University- Massey Cancer Center

Research Area

Biography

Harry D. Bear has not added Biography.
If you are Harry D. Bear and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 6	2011

Other Publications

Article	Year
Collaborative Initiatives in the Care of Early Stage Breast Cancer: Reduction in Variation of Breast-Conserving Therapy. The breast journal\| PubMed ID: 11348345	2000
Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity. Annals of surgical oncology\| PubMed ID: 11829435	2002
Earlier chemotherapy for breast cancer: perhaps too late but still useful. Annals of surgical oncology\| PubMed ID: 12734078	2003
Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag? Journal of the National Cancer Institute\| PubMed ID: 12759377	2003
Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. International journal of radiation oncology, biology, physics\| PubMed ID: 12788173	2003
Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer immunology, immunotherapy : CII\| PubMed ID: 12827306	2003
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. The Surgical clinics of North America\| PubMed ID: 12875604	2003
The impact of physician and hospital volume on the quality of surgical outcomes. Journal of surgical oncology\| PubMed ID: 14502775	2003
Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancer. Journal of surgical oncology\| PubMed ID: 14502777	2003
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowe... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 14559892	2003
Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. International immunology\| PubMed ID: 15262898	2004
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 15837984	2005
Walter Lawrence, Jr.: a tribute to a surgical oncologist. "Been there, done that". Journal of surgical oncology\| PubMed ID: 15895456	2005
Sentinel node micrometastases and non-sentinel nodes in breast cancer: how much do we need to know? Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16567763	2006
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Prot... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16606972	2006
Tumor bed boost omission after negative re-excision in breast-conservation treatment. Annals of surgical oncology\| PubMed ID: 16614879	2006
Reaping the harvest from neoadjuvant therapy for breast cancer: reducing morbidity with sentinel lymph node biopsy. Journal of surgical oncology\| PubMed ID: 17192916	2007
Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nuclear medicine and biology\| PubMed ID: 17921033	2007
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18258986	2008
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18258988	2008
Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them? Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18323543	2008
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer research\| PubMed ID: 18381452	2008
Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastas... Breast cancer research and treatment\| PubMed ID: 18425677	2009
Completion axillary lymph node dissection for breast cancer: immediate versus delayed versus none. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18640928	2008
Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer immunology, immunotherapy : CII\| PubMed ID: 18979098	2009
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. International immunopharmacology\| PubMed ID: 19336265	2009
Effects of surgical excision on survival of patients with stage IV breast cancer. The Journal of surgical research\| PubMed ID: 19375721	2010
IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast cancer research and treatment\| PubMed ID: 19826947	2010
Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. Journal of translational medicine\| PubMed ID: 19849846	2009
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast cancer research and treatment\| PubMed ID: 19898981	2010
Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast cancer research and treatment\| PubMed ID: 20155316	2010
Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surgical oncology clinics of North America\| PubMed ID: 20620930	2010
Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC immunology\| PubMed ID: 21050466	2010
Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. Journal of translational medicine\| PubMed ID: 21453513	2011
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast cancer research and treatment\| PubMed ID: 21479927	2012
Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transg... Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 21670315	2011
Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Molecular cancer research : MCR\| PubMed ID: 21693597	2011
A gene transcription signature of obesity in breast cancer. Breast cancer research and treatment\| PubMed ID: 21750966	2011
Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 21849404	2011
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England journal of medicine\| PubMed ID: 22276821	2012